8-K: Senseonics Reports 18% Revenue Growth in Q2 2024, Advances 365-Day CGM System

Senseonics Holdings, Inc. announced an 18% year-over-year revenue increase for the second quarter of 2024, alongside progress in the development and launch of their next-generation 365-day continuous glucose monitoring system.

Summary

• Senseonics reported a total revenue of $4.9 million for the second quarter of 2024, an increase from $4.1 million in the same period last year.
• U.S. revenue grew to $3.0 million, up from $1.8 million year-over-year, while revenue outside the U.S. decreased to $1.9 million from $2.3 million.
• The company's gross profit for the quarter was $0.3 million, down from $0.4 million in the prior year due to increased fixed manufacturing costs.
• Sales, marketing, and general administrative expenses rose by $1.5 million to $9.0 million, driven by expansion efforts for Eon Care Services and the Mercy collaboration.
• Research and development expenses decreased by $2.0 million to $10.8 million, primarily due to the completion of the 365-day sensor pivotal trial.
• The net loss for the quarter was $20.3 million, or $0.03 per share, compared to a net loss of $20.4 million, or $0.04 per share, in the second quarter of 2023.
• Senseonics maintains its full-year 2024 revenue guidance of $22 million to $24 million.
• The company expects to more than double U.S. new patient starts and increase the global installed base by approximately 50% in 2024 compared to 2023.
• Cash utilization for 2024 is projected to be around $70 million, consistent with 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the revenue growth, progress on the 365-day system, and strategic initiatives. However, the net loss and increased expenses temper the overall outlook.

Positives

• The company experienced an 18% increase in revenue compared to the same quarter last year.
• U.S. revenue showed strong growth, indicating increasing market penetration.
• The 365-day Eversense system is on track for a planned launch in the fourth quarter of 2024.
• The collaboration with Mercy healthcare system is progressing, potentially leading to wider adoption of Eversense.
• The establishment of Eon Care Services should improve access to Eversense insertion procedures and training.
• The initiation of first-in-human testing for the Gemini System demonstrates innovation in their product pipeline.
• The company is maintaining its full-year revenue guidance, suggesting confidence in future performance.

Negatives

• Gross profit decreased to $0.3 million from $0.4 million year-over-year due to higher fixed manufacturing costs.
• Sales, marketing, and general administrative expenses increased by $1.5 million, impacting profitability.
• Revenue outside the U.S. decreased compared to the prior year period.
• The company reported a net loss of $20.3 million for the quarter.

Risks

• The launch of the 365-day Eversense system is dependent on FDA clearance, which is not guaranteed.
• Inventory dynamics related to the 365-day product launch are expected to impact third-quarter sales.
• The company's success is dependent on the execution of commercial initiatives by its partner, Ascensia Diabetes Care.
• There are uncertainties in insurer, regulatory, and administrative processes that could affect the company's performance.
• The company faces risks related to the development and registration of new technologies and solutions.
• The current economic environment could impact the company's ability to achieve its goals.

Future Outlook

Senseonics expects full-year 2024 global net revenue to be between $22 million and $24 million, with a significant increase in U.S. new patient starts and global installed base. The company anticipates sales to accelerate in the fourth quarter due to the 365-day product launch and the Mercy collaboration.

Management Comments

• During the second quarter, the Eversense user base in the U.S. expanded and we advanced key strategic initiatives to position the Company to successfully launch the 365-day Eversense system in the fourth quarter, pending anticipated FDA clearance, said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics.
• We are focused on executing the integration of the Eversense CGM + RPM solution with Mercy, preparing for launch of the 365-day Eversense product, and the progression of exciting offerings in our development pipeline.
• We envision these initiatives serving as the foundation for significant future growth.

Industry Context

This announcement comes as the market for continuous glucose monitoring systems is growing, with increasing demand for long-term implantable solutions. Senseonics is positioning itself to compete with other CGM providers by focusing on long-term implantable technology and remote patient monitoring services.

Comparison to Industry Standards

• Senseonics' revenue growth of 18% year-over-year is a positive sign, but it is important to compare this to the growth rates of competitors like Dexcom and Abbott, which are also experiencing significant growth in the CGM market.
• The company's focus on a 365-day implantable sensor is a differentiator, as most competitors offer shorter-term solutions. However, the success of this product will depend on FDA approval and market adoption.
• The collaboration with Mercy healthcare system is a unique approach that could provide a competitive advantage if it leads to widespread adoption of Eversense.
• The company's net loss of $20.3 million is not unusual for a growth-stage medical technology company, but it will need to demonstrate a path to profitability in the coming years.
• The cash utilization of $70 million is consistent with the previous year, but it is important to monitor this metric to ensure the company has sufficient capital to execute its growth plans.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and progress on the 365-day system, but concerned about the net loss.
• Employees may be motivated by the company's growth and strategic initiatives.
• Customers may benefit from the launch of the 365-day Eversense system and the remote patient monitoring service.
• Suppliers may see increased demand for their products and services.
• Creditors may be reassured by the company's revenue growth and cash position.

Next Steps

• Senseonics will continue to advance the FDA review of the 510(k) submission for the 365-day Eversense system.
• The company will focus on operational readiness activities for the planned fourth-quarter 2024 product launch.
• Senseonics will continue to advance the collaboration with Mercy healthcare system, with initial insertions planned for Q3 2024.
• The company will continue first-in-human testing for the Gemini System.
• Senseonics will host a conference call to discuss these financial results and recent business developments.

Key Dates

Keywords

Senseonics, Eversense, CGM, Continuous Glucose Monitoring, Diabetes, Medical Technology, Implantable Sensor, Revenue, Financial Results, FDA, Mercy Healthcare, Eon Care Services, Gemini System